Lilly holds 60.9% US incretin share as Novo pipeline questions persist
Both drugmakers beat second-quarter estimates and raised guidance, but Novo's shares fell after Wegovy pill revenue came in below expectations.
The wire
- 01Lilly reported 48% year-over-year revenue growth on Mounjaro and Zepbound demand and lifted full-year guidance; its presentation put US obesity and diabetes market share at 60.9% versus Novo's 38.8%.
- 02Analysts said Novo's beat leaned on rebate adjustments and other temporary factors, and that the Wegovy pill miss reflects a broader need for pipeline diversification.
- 03Analysts expect the global market to exceed $100 billion by the 2030s, but both companies face lower US prices, and Jefferies said Novo's quarter leaves many questions open for 2027.
From the source
Read at cnbc.comThe divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
The diverging paths of two GLP-1 drugmakers were on full display this week.